A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)

Reviewer: John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 5 de junio del 2006

Translation for this article does not exist

Related News

ZDN/IFN-α Ups Survival in T-Cell Leukemia/Lymphoma

Nov 4, 2011

Combination of zidovudine, interferon α with chemo prolongs survival in acute, lymphoma ATLL